Exercise-induced bronchospasm: Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines

Gene Colice, William Calhoun

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalWorld Allergy Organization Journal
Volume3
Issue number2
DOIs
StatePublished - 2010

Fingerprint

montelukast
Exercise-Induced Asthma
Albuterol
Asthma
Guidelines
Leukotriene Antagonists
Nebulizers and Vaporizers
Airway Obstruction
Tablets
Exercise

Keywords

  • Airway hyperreactivity
  • Albuterol
  • Asthma
  • Bronchia hyperresponsiveness
  • Exercise-induced bronchospasm
  • Exerciseinduced asthma
  • Montelukast

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

@article{88abf863c66c4863b882870020573d2c,
title = "Exercise-induced bronchospasm: Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines",
abstract = "Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.",
keywords = "Airway hyperreactivity, Albuterol, Asthma, Bronchia hyperresponsiveness, Exercise-induced bronchospasm, Exerciseinduced asthma, Montelukast",
author = "Gene Colice and William Calhoun",
year = "2010",
doi = "10.1097/WOX.0b013e3181d25eac",
language = "English (US)",
volume = "3",
pages = "23--30",
journal = "World Allergy Organization Journal",
issn = "1939-4551",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Exercise-induced bronchospasm

T2 - Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines

AU - Colice, Gene

AU - Calhoun, William

PY - 2010

Y1 - 2010

N2 - Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.

AB - Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.

KW - Airway hyperreactivity

KW - Albuterol

KW - Asthma

KW - Bronchia hyperresponsiveness

KW - Exercise-induced bronchospasm

KW - Exerciseinduced asthma

KW - Montelukast

UR - http://www.scopus.com/inward/record.url?scp=77954904138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954904138&partnerID=8YFLogxK

U2 - 10.1097/WOX.0b013e3181d25eac

DO - 10.1097/WOX.0b013e3181d25eac

M3 - Article

C2 - 24228852

AN - SCOPUS:77954904138

VL - 3

SP - 23

EP - 30

JO - World Allergy Organization Journal

JF - World Allergy Organization Journal

SN - 1939-4551

IS - 2

ER -